Research programme: monoclonal antibodies - arGEN-X/Shire

Drug Profile

Research programme: monoclonal antibodies - arGEN-X/Shire

Latest Information Update: 09 Mar 2015

Price : $50

At a glance

  • Originator arGEN-X
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 18 Feb 2015 arGEN-X in-licenses GS Xceed™ System technology from Lonza
  • 04 Jun 2014 arGEN-X enters into a long-term strategic collaboration with Shire Pharmaceuticals for the discovery and development of differentiated therapeutic antibodies against multiple targets of interest to Shire
  • 20 Sep 2013 Preclinical trials in Undefined indication in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top